Evaluation Only. Created with Aspose.PDF. Copyright 2002-2021 Aspose Pty Ltd.
D. Kułaga et al.
Bioorganic & Medicinal Chemistry Letters xxx (xxxx) xxx
Ipsapirone exhibits anxiolytic, anti-depressant, and anti-aggressive
properties in animal models.12 as it acts as a postsynaptic partial
agonist to 5-HT1AR with Ki = 7.9 nM and no activity to D2R.13–15 In the
literature16–18 there is described only one analogue of ipsapirone with
ethyl linker (A) that does not bind to 5-HT1AR, two analogues of ipsa-
pirone with propyl linker that bind to 5-HT1AR with Ki = 400 nM for B
and Ki = 2 nM for C (revospirone) and four four-carbon analogues of
ipsapirone with known affinity to D2R (four analogues) as well as 5-
HT1AR/5-HT2AR (one analogue) (Table 1). In our previous research19
with saccharin being a terminal moiety of LCAP, we demonstrated that
carbon linker extended up to six carbons may have a beneficial influence
on affinity mostly to D2R (Table 1). Taking into account that acting on
both D2R and 5-HT1AR may have a beneficial influence in treatment of
depression or schizophrenia, the aim of our work is to perform the full
structure activity relationship analysis for ipsapirone analogues to
confirm our hypothesis that elongation of carbon linker has a beneficial
influence on affinity to D2R/5-HT1AR.
In light of the above consideration, to fully perform structure activity
relationship study of ipsapirone, we designed four groups of compounds.
Compounds with flexible butyl, pentyl, hexyl chain and more rigid
xylene linker have been chosen to find out the optimal length of carbon
linker. Additionally, these four groups include various N-arylpiperazines
in order to find their influence on binding to selected receptors (Fig. 1).
In this study, we focused mostly on dual D2R/5-HT1AR effect, however,
to examine their selectivity, binding to 5-HT2AR, 5-HT6R and 5-HT7R
were examined as well. We used molecular modelling to support the SAR
study.
Designed compounds were obtained in solvent-free reactions with
microwave irradiation. The procedure has already been described in our
previous publications.19,31 Ligands from groups I, II and IV were ob-
tained in three independent synthetic routes using two-step reactions
(Scheme 1 and Scheme 2). For SAR study, ligands from group of III were
taken from our previous publication.19
In the first step, a saccharin 1 is N-alkylated with appropriate alkyl
halide 2i-2k. The first step was carried out in the presence of 3 equiv-
alents of potassium carbonate, 0.1 equivalents of tetrabutylammonium
bromide (TBAB), and 2–3 drops of N,N-dimethylformamide (DMF) or
acetonitrile (ACN). Intermediates 3i and 3k were purified via crystalli-
zation from methanol, while 3j was purified using column chromatog-
raphy. Reaction conditions for the second step were similar to those for
the first one. Final products were purified using column chromatog-
raphy. Pure ligands were transformed into HCl salts and subjected to
radioligand assays.
In the medicinal chemistry, hit-to-lead is a well-known approach,
where a desirable pharmacological profile for protein/receptor is ex-
pected via various chemical modifications.20 In the literature there are
numerous reports about SAR (Structure Activity Relationship) study
within LCAPs (Long Chain Arylpiperazines) including carbon linker and
various arylpiperazine exchange (Table 2).7,21–24 In general, N-arylpi-
perazine itself exhibits moderate affinity and selectivity to the following
receptors: serotonin21, dopamine25, noradrenaline26 as well as mono-
amine transporters.9–10 The functionalization of N-arylpiperazine by
introducing a long chain core attached to the basic nitrogen of pipera-
zine core may have beneficial influence on affinity to receptors.21 For
example, 1-(2-methoxyphenyl)piperazine binds to 5-HT1AR with Ki =
68 nM. Introducing phthalimide with ethyl linker (I)to basic nitrogen
atom resulted in loss of activity to 5-HT1AR (Ki > 1000 nM) (Table 2).
Further elongation of carbon linker resulted in gain of affinity to 5-
HT1AR in the following pattern: propyl linker (J) Ki = 13 nM21, butyl
The aim of this research was to elucidate SAR of LACPs being
saccharin derivatives with increased affinity to D2R/5-HT1AR. All li-
gands were tested in radioligand binding assays according to a known
procedure.32 The assays were performed via the displacement of the
respective radioligands from cloned human receptors, all stably
expressed in HEK293 cells (except for 5-HT2AR which was expressed in
CHO cells): [3H]-8-OH-DPAT for 5-HT1AR, [3H]-ketanserin for 5-HT2AR,
[3H]-LSD for 5-HT6R, [3H]-5-CT for 5-HT7R and [3H]-raclopride for
D2R.
linker (K – NAN-190) Ki = 0.6 nM21, pentyl linker (L) Ki = 7.2 nM27
,
hexyl linker (M) Ki = 22 nM.27 According to the NAN-190 SAR study,
optimal carbon linker length is around 4 atoms. Shorter linker decreases
affinity, and similar effects are observed for longer linkers as well. For
salicylamide and 1,3-benzoxazine-2,4-dione in terminal position, the
same trend has been observed (Table 2). Considering the SAR study for
trazodone, elongation of carbon linker up to 6 atoms resulted in a near 5-
fold increase of affinity to 5-HT1AR.23 Further research revealed that
using other N-arylpiperazines such as 1-(2-methoxyphenyl)piperazine
or 1-(3-methoxyphenyl)piperazine instead of 1-(3-chlorophenyl)piper-
azine dramatically increased affinity to D2R/5-HT1AR (Table 3).
According to Structure – Linker Relationship, most of the obtained
ligands exhibited affinity to the mixed D2R/5-HT1AR profile. In the
group of ligands with no substituents of the N-arylpiperazine moiety
(5a, 5b, 5c), slightly decreased activity was observed upon linker chain
elongation. Ligands still exhibited high affinity to 5-HT1AR with Ki ≤ 20
nM. The opposite pattern was observed with respect to D2R. We
observed moderate or no affinity to the remainder of tested receptors.
Because saccharin core is structurally similar to phthalimide, we ex-
pected that in case of 1-(2-methoxyphenyl)piperazine (ligands 5b, 6b
Table 1
Saccharin carbon linker comparison on affinity (Ki [nM]) to D2R/5-HT1AR/5-HT2AR.16–19
Ligand No.
n
Ar
h-D1
h-D2
h-D3
h-D4
h-D5
h-5-HT1A
h-5-HT2A
h-5-HT2C
h-α1
A
2
3
3
4
3-CF3-Ph
3-CF3-Ph
2-Pyrimidinyl
Ph
nd
nd
nd
nd
nd
NA
nd
nd
nd
nd
nd
nd
nd
136
36
NA
79
nd
nd
NA
400
2
nd
nd
NA
nd
nd
nd
NA
nd
nd
nd
nd
nd
nd
nd
B
nd
nd
nd
700
nd
C*
D
nd
nd
nd
38
66
1629
230
1756
1132
nd
nd
nd
E
4-Cl-Ph
177
113
360
1600
287
107
187
nd
nd
nd
F = 5e
G
3-CF3-Ph
2-OMe-Ph
2-Pyrimidinyl
100
nd
2250
nd
1500
nd
H**
=5f
7a
7d
7e
7b
7f
7.9
14,980
229
6
Ph
nd
nd
na
na
na
48
28
7
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
20
84
25
91
24
321
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
4-Cl-Ph
3-CF3-Ph
2-OMe-Ph
2-Pyrimidinyl
167
nd
61
51
183
NA – not active (Ki > 5
μM) nd - not determined, * - revospirone, ** - ipsapirone, h-human receptor type
2